Enhancing metabolic action of FGF21 through adipocyte Connexin43 gap junction channels
Enhancing metabolic action of FGF21 through adipocyte Connexin43 gap junction channels
批准号:
10716136
负责人:
Yi Zhu
金额:
$46.19万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2027-08-31
关键词:
AdipocytesAdipose tissueAdrenergic AgonistsAgonistBody Weight decreasedBrainBrain regionBrown FatCellsChemosensitizationClinical TrialsConnexin 43ConnexinsCouplingDataDevelopmentDiffusionEnergy MetabolismGap JunctionsGenetic ModelsHormonesHumanHyperglycemiaLipidsLiteratureLiverMediatingMetabolicMetabolic DiseasesMetabolismModelingMusNeuronsNon-Insulin-Dependent Diabetes MellitusObesityOrganPeripheralPharmacologic SubstanceProcessProtein IsoformsProteinsProteomicsPublicationsRefractoryRespirationRodentSafetySerumSignal TransductionTestingTherapeuticTissuesTriglyceridesType 2 diabeticVascularizationWorkanalogblood glucose regulationbrain tissuediabetic patientfibroblast growth factor 21gap junction channelglycemic controlhydrophilicityimprovedinsightinsulin sensitivitymetabolomicsmouse modelnovelobese patientsobese personoverexpressionpharmacologicresponsetargeted agent
中文摘要
项目总结/摘要
肥胖和2型糖尿病(T2 D)患者仍然需要具有增强疗效和改善安全性的治疗方法。
脂肪组织是治疗肥胖和T2 D的有希望的靶点。然而,药物制剂通常不能
由于脂肪细胞的巨大尺寸和血管化不足,
肥胖受试者。我们以前的工作表明,连接蛋白43(Cx43)间隙连接被激活,并诱导
连接相邻的脂肪细胞以在多个细胞之间共享有限的交感神经元输入。我们最近
发表揭示了连接蛋白43间隙连接通道激活剂达奈肽显著增强了
脂肪细胞偶联和成纤维细胞生长因子21(FGF 21)的代谢功效。初步工作表明,
脂肪细胞特异性Cx43过表达增强了FGF 21对体重减轻和改善肥胖的功效。
代谢,在很大程度上概括了达那肽对FGF 21的增强作用。根据我们初步的
数据和文献,我们提出了一个层次和协调的“点火燃烧”模型,FGF 21
参与大脑和脂肪组织来调节全身代谢。增强Cx43间隙连接
脂肪细胞之间的相互作用促进了来自大脑的FGF 21激活的交感神经信号的传播,
脂肪细胞的自主FGF 21信号。由于Klb在脑中的低表达,我们假设脑通常
获得足够的FGF 21输入。相比之下,脂肪组织,特别是来自肥胖受试者的脂肪组织,
受神经支配且对FGF 21刺激的细胞应答不敏感。几种新的小鼠模型和FGF 21
类似物的开发,我们建议(A)了解脂肪细胞Cx43的间隙连接的重要性,
(B)测试“点燃-燃烧”模型,以及
增强脂肪组织中的“燃烧”在改善FGF 21功效方面的重要性。我们还将测试
(C)一种正交的,逐步的方法来实现Cx43间隙连接和FGF 21双重激动,
脂肪组织总之,这些研究将为FGF 21如何协调多种细胞因子提供新的见解。
器官调节能量消耗以及靶向脂肪组织间隙连接如何增强脂肪
组织药物参与。在这个过程中,我们还将产生几种新的FGF 21类似物,
作为肥胖症和T2 D的潜在疗法进行测试。
英文摘要
PROJECT SUMMARY/ABSTRACT
Obese and Type 2 diabetic (T2D) patients still need therapeutics with enhanced efficacy and improved safety.
Adipose tissue is a promising target for treating obesity and T2D. However, pharmacological agents usually fail
to effectively engage adipocytes due to their extraordinary size and insufficient vascularization, especially in
obese subjects. Our previous work suggests connexin43 (Cx43) gap junctions are activated and induced to
connect neighboring adipocytes to share limited sympathetic neuronal inputs among multiple cells. Our recent
publication reveals that danegaptide, a Connexin43 gap junction channel activator, significantly enhances
adipocyte coupling and the metabolic efficacy of fibroblast growth factor 21 (FGF21). Preliminary work showed
adipocyte-specific Cx43 overexpression enhanced FGF21’s efficacy on weight loss and improvement in
metabolism, largely recapitulating the danegaptide’s potentiation effect on FGF21. Based on our preliminary
data and literature, we propose a hierarchical and coordinated “ignition-combustion” model by which FGF21
engages the brain and adipose tissue to regulate systemic metabolism. Enhancing Cx43 gap junctions
between adipocytes facilitates the dissemination of FGF21-activated sympathetic signals from the brain and
adipocytes’ autonomous FGF21 signals. Due to low Klb expression in the brain, we postulate the brain usually
receives sufficient FGF21 inputs. In contrast, adipose tissue, especially from obese subjects, is insufficiently
innervated and refractory to FGF21-stimulated cellular response. With several new mouse models and FGF21
analogs developed, we propose to (A) understand the importance of the adipocyte Cx43’s gap junction
channel function in enhancing FGF21’s metabolic benefits, (B) test the “ignition-combustion” model, and the
importance of enhancing “combustion” in the adipose tissue in improving FGF21’s efficacy. We will also test
(C) an orthogonal, step-by-step approach to achieving Cx43 gap junction and FGF21 dual agonism in the
adipose tissue. Altogether, these studies will provide novel insights into how FGF21 coordinates multiple
organs to regulate energy expenditure and how targeting adipose tissue gap junctions can enhance adipose
tissue pharmaceutical engagement. In this process, we will also generate several new FGF21 analogs that can
be tested as potential therapeutics for obesity and T2D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Postprandial activation of hyaluronan-MARCO axis contributes to systemic chronic inflammation
-
批准号:10712757
-
项目类别:
-
资助金额:$43.38万
-
财政年份:2023
-
负责人:Yi Zhu
-
依托单位:
Investigating the impact of peripheral senescent cells on the brain
-
批准号:10670484
-
项目类别:
-
资助金额:$42.36万
-
财政年份:2022
-
负责人:Yi Zhu
-
依托单位:
Gap Junction Dependent and Independent Roles of Connexin43 in Metabolic Tissues
-
批准号:10062957
-
项目类别:
-
资助金额:$24.45万
-
财政年份:2019
-
负责人:Yi Zhu
-
依托单位:
Gap Junction Dependent and Independent Roles of Connexin43 in Metabolic Tissues
-
批准号:10056398
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2019
-
负责人:Yi Zhu
-
依托单位:
Gap Junction Dependent and Independent Roles of Connexin43 in Metabolic Tissues
-
批准号:10301010
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2019
-
负责人:Yi Zhu
-
依托单位:
海外基金